7:["$","div",null,{"className":"","children":[["$","main",null,{"role":"main","className":"w-full text-white sr-only","children":[["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative z-10","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","header",null,{"className":"flex flex-col gap-4 pt-8 sm:pt-12","children":["$","div",null,{"className":"flex flex-col items-center gap-6","children":[["$","div",null,{"className":"relative","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172970.jpeg","alt":"Cybin logo","width":120,"height":120,"className":"rounded-lg object-contain","priority":true}]}],["$","div",null,{"className":"text-center","children":[["$","h1",null,{"className":"text-2xl md:text-4xl lg:text-5xl font-bold text-white mb-4","children":["Cybin",": ","Psychedelic Potential"]}],["$","h2",null,{"className":"text-lg md:text-xl text-gray-300 max-w-3xl mx-auto","children":"Cybin is paving the way for psychedelic medicine to treat mental health disorders, positioning itself at the forefront of a growing industry that could revolutionize psychiatry."}]]}],["$","div",null,{"className":"flex flex-col items-center gap-2 text-center","children":[["$","div",null,{"className":"flex items-center gap-2 text-sm text-gray-400","children":[["$","span",null,{"children":["NYSEAMERICAN",":"]}],["$","span",null,{"className":"font-medium text-white","children":"CYBN"}]]}],["$","div",null,{"className":"flex items-center gap-3","children":[["$","span",null,{"className":"text-2xl font-bold text-white","children":"$$8.05"}],["$","span",null,{"className":"text-sm font-medium text-red-400","children":"-3.57%"}]]}]]}],["$","div",null,{"className":"flex flex-wrap justify-center gap-4 text-sm text-gray-400","children":[["$","span",null,{"children":["Updated: ","May 02, 2025"]}],["$","div",null,{"className":"flex flex-wrap gap-2","children":[["$","span","81",{"className":"bg-gray-800 px-2 py-1 rounded","children":"Healthcare"}]]}]]}],["$","div",null,{"className":"flex flex-wrap justify-center gap-2 text-xs","children":[["$","span",null,{"className":"bg-blue-900/30 text-blue-300 px-2 py-1 rounded","children":"micro"}],["$","span",null,{"className":"bg-green-900/30 text-green-300 px-2 py-1 rounded","children":"canada"}]]}]]}]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"id":"bull-bear-case","aria-label":"Bull & Bear Case","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Bull & Bear Case"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"An overview of the main reasons to invest and the key risks involved."}]]}],["$","div",null,{"className":"flex gap-8 flex-col xl:flex-row","children":[["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-6","children":["$","h3",null,{"className":"text-lg font-medium text-white mb-2 pb-2 border-b border-[#3F3D42]","children":"Bull Case"}]}],["$","div",null,{"className":"space-y-4","children":[["$","article","0",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Expanding Market for Psychedelic Medicine"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"The global mental health crisis and the promise of psychedelic medicine for depression, PTSD, and addiction present Cybin with a unique opportunity to lead in a rapidly growing market."}]]}]]}],["$","article","1",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Advancing Clinical Pipeline"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Cybin’s lead candidate, CYB003, is in Phase 3 trials for Major Depressive Disorder, with positive preliminary results. The company is also expanding its pipeline into other mental health conditions like anxiety and addiction."}]]}]]}],["$","article","2",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-green-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 5.778 8.947 9.275c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.032-.19-.12-.366-.297L6.725 8.06c-.176-.176-.264-.264-.366-.297a.444.444 0 0 0-.274 0c-.102.033-.19.12-.366.297l-2.164 2.164m8.89-4.445H9.332m3.111 0V8.89"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Strategic Partnerships and Industry Momentum"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Cybin benefits from strong partnerships with academic and industry leaders, positioning it well to leverage growing institutional interest and regulatory support for psychedelic medicine as the industry gains momentum."}]]}]]}]]}]]}]}]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-6","children":["$","h3",null,{"className":"text-lg font-medium text-white mb-2 pb-2 border-b border-[#3F3D42]","children":"Bear Case"}]}],["$","div",null,{"className":"space-y-4","children":[["$","article","0",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Strategic Partnerships and Industry Momentum"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Despite progress, regulatory approval for psychedelics remains uncertain. Unexpected delays or challenges from regulatory bodies could push back timelines, impacting market entry and revenue potential."}]]}]]}],["$","article","1",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Competition in Psychedelic Market"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"The psychedelics market is increasingly crowded. Competitors with similar treatment models or more established pipelines could limit Cybin’s market share, putting pressure on pricing and growth."}]]}]]}],["$","article","2",{"className":"flex gap-3 items-start py-2","children":[["$","div",null,{"className":"mt-1 flex-shrink-0","children":["$","div",null,{"className":"w-4 h-4 rounded-full bg-red-800 flex items-center justify-center","children":["$","svg",null,{"width":"12","height":"12","viewBox":"0 0 16 16","fill":"none","xmlns":"http://www.w3.org/2000/svg","children":["$","path",null,{"stroke":"#D9D7DB","strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":"1.5","d":"M12.444 10.223 8.947 6.726c-.176-.176-.264-.264-.366-.297a.445.445 0 0 0-.274 0c-.102.033-.19.12-.366.297L6.725 7.942c-.176.176-.264.264-.366.297a.444.444 0 0 1-.274 0c-.102-.033-.19-.12-.366-.297L3.555 5.778m8.89 4.445H9.332m3.111 0V7.112"}]}]}]}],["$","div",null,{"className":"flex-1","children":[["$","h4",null,{"className":"font-medium text-sm text-white mb-1","children":"Execution and Commercialization Risks"}],["$","p",null,{"className":"text-xs text-[#BAB9BD]","children":"Cybin faces the challenge of executing its post-approval commercialization plan, managing partnerships, and gaining market access. Effective execution will be crucial for achieving long-term growth and maintaining competitive advantages."}]]}]]}]]}]]}]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"id":"executive-summary","aria-label":"Executive Summary","children":[["$","header",null,{"children":["$","h2",null,{"className":"text-xl text-white font-semibold md:text-4xl flex-1 text-center mb-10","children":"Executive Summary"}]}],["$","div",null,{"className":"flex gap-8 flex-col-reverse md:flex-row justify-center","children":[["$","article",null,{"className":"w-full md:w-[584px] flex flex-col items-start","children":[["$","h3",null,{"className":"md:text-lg font-medium text-white mb-4 text-center","children":"Strong Position in the Psychedelics Space"}],["$","div",null,{"className":" m-0 text-[#D9D7DB] prose prose-invert max-w-none","dangerouslySetInnerHTML":{"__html":"

Cybin Inc. is a biotechnology company developing novel psychedelic therapies aimed at addressing mental health conditions, including major depressive disorder (MDD), anxiety, and addiction. With a focus on developing psilocybin-based treatments and innovative delivery mechanisms, Cybin is conducting pivotal clinical trials to prove their efficacy in treating these conditions.

Cybin’s business model is driven by the large unmet need in mental health, the accelerating shift towards psychedelic-assisted treatments, and its innovative clinical pipeline. The company’s strong position in the psychedelics space, with promising clinical trials, could position it for significant growth as more jurisdictions explore legalizing psychedelic therapies.

"}}],["$","div",null,{"className":"mt-10","children":["$","a",null,{"href":"https://ir.cybin.com/overview/default.aspx","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center px-6 py-3 bg-blue-600 hover:bg-blue-700 text-white font-medium rounded-lg transition-colors duration-200","aria-label":"Visit Investor Relations - opens in new tab","children":"Investor Relations"}]}]]}],["$","div",null,{"className":"w-full md:w-6/12","children":["$","div",null,{"className":"relative w-full aspect-video lg:w-[560px]","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/qZWGF2M4vwE","title":"CEO Interview","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy","style":{"borderRadius":"4px","overflow":"hidden"}}]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"investment-thesis","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Investment Thesis","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Investment Thesis"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Overview of buy and sell case of the business."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Why Invest?"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"Key pieces of information about the business that you need to know about."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Expanding Market for Psychedelic Medicine"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

The mental health crisis is worsening globally, with traditional treatments often failing to deliver meaningful results. This gap presents a massive opportunity for psychedelic medicines, which have shown promising effects in treating depression, PTSD, and addiction. Cybin, with its innovative approach and strong clinical pipeline, stands at the forefront of this industry shift. As public perception and regulatory hurdles begin to ease, Cybin is poised to capitalize on this new era of mental health treatment. This growing market could provide significant long-term growth opportunities for Cybin as more jurisdictions embrace the therapeutic potential of psychedelics.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Advancing Clinical Pipeline"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin has one of the most promising pipelines in the psychedelic space, with its lead candidate CYB003, a psilocybin-based therapy, currently undergoing Phase 3 clinical trials for Major Depressive Disorder (MDD). With a rigorous scientific approach and positive preliminary results, Cybin’s progress in clinical trials positions it well for eventual approval. Moreover, the company is expanding its research into additional mental health disorders, such as anxiety and addiction, further diversifying its clinical pipeline. This broad focus enhances Cybin’s potential for long-term success in a rapidly evolving market.

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Strategic Partnerships and Industry Momentum"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin has built a strong network of collaborations with leading academic institutions and industry players, enhancing its credibility and advancing its clinical capabilities. The psychedelics industry has gained significant momentum in recent years, with increased interest from institutional investors and governments. Cybin’s ability to secure strategic partnerships and leverage industry momentum positions it well for rapid growth. Additionally, the public’s growing acceptance of psychedelics, fueled by successful clinical trials and regulatory changes, supports the broader adoption of its therapies, further solidifying Cybin’s position in the market.

"}}]]}]]}]}]]}],["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Catalysts"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"The key events that could drive investment opportunities and shift markets."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Near term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Ongoing Phase 3 Trial Progress for CYB003
The ongoing Phase 3 trial for CYB003, a psilocybin-based therapy for Major Depressive Disorder, represents a critical short-term catalyst. Positive results could expedite approval and increase investor confidence in Cybin’s clinical pipeline, driving the stock price higher.
Regulatory Updates and Policy Shifts
Changes in legislation and shifting public attitudes toward psychedelic therapies are key short-term catalysts. Regulatory approvals, particularly in North America and Europe, could significantly boost the momentum for Cybin’s treatments, making these updates crucial for short-term growth.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-yellow-900/30 text-yellow-300","children":"Medium term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Expansion into New Indications
Cybin is expanding its research beyond depression to include indications like anxiety and addiction. The potential approval and subsequent success in these areas could drive significant revenue growth and diversify the company’s portfolio, acting as a medium-term catalyst.
Strategic Partnerships and Licensing Deals
In the medium term, Cybin’s ability to forge strategic partnerships with pharmaceutical companies or healthcare providers will play a critical role in accelerating product development and commercialization. Licensing deals or collaborations could further strengthen its pipeline and provide additional revenue streams.

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4 flex items-center gap-3","children":[["$","span",null,{"className":"px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Long term"}],"$undefined"]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Market Adoption and Integration of Psychedelic Medicine
Long-term catalysts include the growing acceptance and adoption of psychedelic-assisted treatments for mental health. As the global healthcare system continues to embrace alternative treatments for depression, anxiety, and addiction, Cybin could see widespread integration of its therapies, leading to sustained growth.
Commercialization of CYB003 and Other Therapies
Once regulatory approvals are obtained, Cybin’s therapies, particularly CYB003, could become major revenue drivers. Long-term, Cybin’s ability to successfully commercialize its products across global markets and implement its pricing strategy will determine the company’s position as a market leader in psychedelic medicine.

"}}]]}]]}]}]]}],["$","div",null,{"className":"flex flex-col xl:flex-row gap-8","children":[["$","div",null,{"className":"lg:w-[378px] pt-4","children":[["$","h3",null,{"className":"text-xl font-medium text-white mb-2","children":"Key Risks"}],["$","p",null,{"className":"text-[#D9D7DB]","children":"Key pieces of information about the business risks that you need to know about."}]]}],["$","div",null,{"className":"flex-1","children":["$","div",null,{"className":"grid gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Regulatory Delays and Uncertainty"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

The path to FDA approval and widespread adoption of psychedelic therapies is fraught with regulatory hurdles. Delays or rejections in the approval process could extend Cybin’s time to market, slowing revenue generation and impeding growth. Given the evolving regulatory landscape, any unforeseen changes in policy or increased scrutiny on psychedelic treatments could create additional barriers, affecting both timelines and market confidence.

"}}]]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Competitive Landscape"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

The psychedelic medicine space is becoming increasingly competitive, with numerous players pursuing similar therapies. Established companies or new entrants with better-funded trials or differentiated products could capture a larger share of the market. Cybin must continually innovate and demonstrate superior clinical outcomes to maintain its leadership position. The race for FDA approval could also lead to market fragmentation, making it harder for Cybin to maintain its competitive edge.

"}}]]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg p-6 hover:border-[#FFFFFF30] transition-colors duration-200","children":[["$","header",null,{"className":"mb-4","children":["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Execution Risks and Commercialization Challenges"}]}],["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin's success hinges on its ability to execute its clinical trials efficiently and scale its operations. Challenges in trial recruitment, adverse results, or delays in research could hinder progress. Furthermore, while the market for psychedelic therapies is promising, commercialization poses its own risks. The company must navigate complex distribution channels, regulatory hurdles, and public perception to successfully market and monetize its therapies. Any misstep in execution could negatively impact financial results and shareholder value.

"}}]]}]]}]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"experts","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Experts","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Follow the Experts"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence. "}]]}],["$","div",null,{"className":"space-y-12","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162586.jpeg","alt":"Biospace profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Biospace"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Biopharma Publications"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["115k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/biospace","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Biospace's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/company/biospaceinc/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Biospace's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://www.biospace.com/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Biospace's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"article"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Anxiety disorders affect over 40 million adults in the United States each year. In the U.S., GAD is the most common anxiety disorder seen in primary care, with a 12-month prevalence of 2.9%\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.biospace.com/cybin-initiates-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder#:~:text=Anxiety%20disorders%20affect%20over%2040%20million%20adults%20in%20the%20United%20States%20each%20year.3%20In%20the%20U.S.%2C%20GAD%20is%20the%20most%20common%20anxiety%20disorder%20seen%20in%20primary%20care%2C%20with%20a%2012%2Dmonth%20prevalence%20of%202.9%25","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","1",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"article"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Despite the use of existing therapies, 50% of patients with GAD do not respond to first line treatment with antidepressants such as SSRIs and SNRIs\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.biospace.com/cybin-initiates-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder#:~:text=Despite%20the%20use%20of%20existing%20therapies%2C%2050%25%20of%20patients%20with%20GAD%20do%20not%20respond%20to%20first%20line%20treatment%20with%20antidepressants%20such%20as%20SSRIs%20and%20SNRIs4%2C%20highlighting%20a%20large%20treatment%20gap%20and%20urgent%20need%20for%20improved%20therapeutic%20options","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162890.jpeg","alt":"Nature Mental Health profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Nature Mental Health"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Health Journal publication"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["5k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/NatMentHealth","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Nature Mental Health's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],null,["$","a",null,{"href":"https://www.nature.com/natmentalhealth/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Nature Mental Health's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Psilocybin & escitalopram create different reconfigurations in the global functional hierarchy of brain dynamics in people with major depressive disorder\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/NatMentHealth/status/1820817244055609466","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724163076.jpeg","alt":"Drug Science profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Drug Science"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Independent Scientific body"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["25.2k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/Drug_Science","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Drug Science's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],null,["$","a",null,{"href":"https://www.drugscience.org.uk/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Drug Science's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Mental health treatment has seen little innovation over the past 50 years. Recent research shows psychedelics can be effective for depression and PTSD. There is growing support from professionals and patients\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/Drug_Science/status/1793564380506055063","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","3",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233592.jpeg","alt":"Dr Bart Ellenbroek profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Dr Bart Ellenbroek"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Professor of Psychology"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["1.3k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[null,["$","a",null,{"href":"https://www.linkedin.com/in/bartellenbroek/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Dr Bart Ellenbroek's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://people.wgtn.ac.nz/bart.ellenbroek","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Dr Bart Ellenbroek's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"youtube"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"By 2030 mental health associated costs will be 6 trillion dollars. To put that into perspective it is more than the cost for cancer, diabetes and chronic respiratory diseases combined\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://youtu.be/Ij5hjgsFohw?si=1t0A44LRhwPC8c-E","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Watch - opens in new tab","children":["Watch",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","4",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162443.jpeg","alt":"Psychedelic Finance profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Psychedelic Finance"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Investment news in Psychedelic industry"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["21.9k"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/Psych_Fin","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Psychedelic Finance's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/company/forbes-magazine/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Psychedelic Finance's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://www.forbes.com","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Psychedelic Finance's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"x"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Mental healthcare and addiction treatments have not had any meaningful breakthroughs in decades. The psychedelic movement is happening because we urgently need new answers.\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://x.com/Psych_Fin/status/1706300982483702143","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"See more - opens in new tab","children":["See more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","5",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724163576.jpeg","alt":"Forbes profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Forbes"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Information"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["20.1m"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[["$","a",null,{"href":"https://x.com/Forbes","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Forbes's X profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"}]}]}],["$","a",null,{"href":"https://www.linkedin.com/company/forbes-magazine/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Forbes's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],["$","a",null,{"href":"https://www.forbes.com","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"Visit Forbes's website - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M21 12a9 9 0 01-9 9m9-9a9 9 0 00-9-9m9 9H3m9 9v-9m0-9v9m0 9c-5 0-9-4-9-9s4-9 9-9"}]}]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"article"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"The psychedelic drug market is projected to soar to $7.2 billion by 2029, reflecting a 55% compound annual growth rate (CAGR) and further showing its powerful potential in the field of medicine.\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.forbes.com/sites/benjaminadams/2023/09/29/these-three-drugs-could-make-up-over-half-of-forecasted-psychedelic-sales-by-2029/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","1",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"article"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"By 2029, the top three psychedelic drugs—Atai Life Sciences/Otsuka Pharmaceutical’s PCN-101, Cybin’s CYB-003, and Small Pharma’s SPL-026—are projected to represent 52% of the market’s forecasted sales\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://www.forbes.com/sites/benjaminadams/2023/09/29/these-three-drugs-could-make-up-over-half-of-forecasted-psychedelic-sales-by-2029/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}],["$","article","6",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"flex flex-col md:flex-row gap-6 mb-6","children":[["$","div",null,{"className":"flex-shrink-0","children":["$","div",null,{"className":"relative w-24 h-24 md:w-32 md:h-32 mx-auto md:mx-0","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1729170126.jpeg","alt":"Jason Najum profile","fill":true,"className":"rounded-full object-cover","sizes":"(max-width: 768px) 96px, 128px"}]}]}],["$","div",null,{"className":"flex-1 text-center md:text-left","children":[["$","h3",null,{"className":"text-xl md:text-2xl font-semibold text-white mb-2","children":"Jason Najum"}],["$","p",null,{"className":"text-blue-400 font-medium mb-2","children":"Analyst"}],["$","p",null,{"className":"text-gray-300 text-sm","children":["579"," audience"]}],["$","div",null,{"className":"flex justify-center md:justify-start gap-4 mt-4","children":[null,["$","a",null,{"href":"https://www.linkedin.com/in/jason-najum-36a905169/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-gray-400 hover:text-white transition-colors duration-200","aria-label":"View Jason Najum's LinkedIn profile - opens in new tab","children":["$","svg",null,{"className":"w-5 h-5","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}]}],null]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-4","children":"Expert Insights"}],["$","div",null,{"className":"grid gap-4","children":[["$","div","0",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"seeking_alpha"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"After only two doses at 16 milligrams, 75% of those patients were responding to treatment and no longer met the criteria for depression — meaning 75% of patients were in remission from depression after just two doses.\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=After%20only%20two%20doses%20at%2016%20milligrams%2C%2075%25%20of%20those%20patients%20were%20responding%20to%20treatment%20and%20no%20longer%20met%20the%20criteria%20for%20depression%20%E2%80%94%20meaning%2075%25%20of%20patients%20were%20in%20remission%20from%20depression%20after%20just%20two%20doses.","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","1",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"seeking_alpha"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Cybin could be the best value bet among this group of biotech pioneers\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=Cybin%20could%20be%20the%20best%20value%20bet%20among%20this%20group%20of%20biotech%20pioneers.","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","2",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"seeking_alpha"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"Cybin offers a very interesting entry point for investors looking to capitalize on the growth potential of the psychedelic medicine market.\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}],["$","div","3",{"className":"bg-[#0F0E13] border border-[#FFFFFF10] rounded-lg p-4","children":[["$","div",null,{"className":"flex items-center justify-between mb-3","children":["$","span",null,{"className":"text-xs font-medium text-blue-400 bg-blue-900/20 px-2 py-1 rounded","children":"seeking_alpha"}]}],null,["$","div",null,{"className":"text-gray-300 prose prose-invert max-w-none prose-sm mb-4","dangerouslySetInnerHTML":{"__html":"\"The data show that Cybin’s CYB003 has scored over 10 times better in depression symptoms vs historic competitors\""}}],false,false,["$","div",null,{"className":"mt-4","children":["$","a",null,{"href":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=the%20data%20show%20that%20Cybin%E2%80%99s%20CYB003%20has%20scored%20over%2010%20times%20better%20in%20depression%20symptoms%20vs%20historic%20competitors","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read more - opens in new tab","children":["Read more",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]]}]]}]]}]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"investor-materials","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Investor Materials","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Investor Materials"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Access the most recent investor updates published by the company."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div","0",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Key Investor Materials"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 gap-6","children":[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/8mP-z_I6cAk","title":"R&D briefing November 2023","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Article"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Initiates-PARADIGM-A-Multinational-Pivotal-Phase-3-Program-Evaluating-CYB003-for-the-Adjunctive-Treatment-of-Major-Depressive-Disorder-and-Reports-Second-Quarter-Financial-Results/default.aspx","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Corporate Presentation September 2024"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://s28.q4cdn.com/259445127/files/CYBN-Corporate-Deck-September-2024-Website-Final.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: Corporate Presentation September 2024 - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"CYB003 Breakthrough Therapy Designation and Phase 2 Durability Data in MDD"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://s28.q4cdn.com/259445127/files/CYBN-CYB003-Program-Update-March-13-2024-Final.pdf","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: CYB003 Breakthrough Therapy Designation and Phase 2 Durability Data in MDD - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","1",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Pipeline"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 gap-6","children":[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/dUn2QI5Mtgs","title":"Pipeline","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-blue-900/30 text-blue-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"Leading the Industry in Therapeutic Development & Innovative Drug Delivery. 16 patents cover a range of novel psychedelic compounds."}],["$","footer",null,{"children":["$","a",null,{"href":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Grant-of-Additional-U.S.-Patent-in-Support-of-its-CYB003-Breakthrough-Therapy-Program-for-Major-Depressive-Disorder/default.aspx","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","1",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Completion-of-FDA-Type-B-Initial-Breakthrough-Therapy-Meeting-and-Plans-for-CYB003-Phase-3-Program-in-Major-Depressive-Disorder/default.aspx","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}],["$","article","2",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Development Pipeline"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-red-900/30 text-red-300","children":"PDF"}]]}],null,["$","footer",null,{"children":["$","a",null,{"href":"https://cybin.com/development-pipeline/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View PDF: Development Pipeline - opens in new tab","children":["View PDF",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"external-insights","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"External Insights","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"External Insights"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"A curated collection of third-party content relevant to the company and sector to help inform your investment decision."}]]}],["$","div",null,{"className":"space-y-16","children":[["$","div","0",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Impact"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/QCQoBAzMP2E?start=0","title":"Ted talk","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/D2wuKe5dAJw?start=0","title":"How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/0KdG6aIcKNGlK9KdYjmOst?si=83bf93d2a14846fa","title":"Interview","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Has Cybin hit the biggest breakthrough in 40 years to treat psychiatric disorders?"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years."}],["$","footer",null,{"children":["$","a",null,{"href":"https://www.outsourcing-pharma.com/Article/2024/05/30/Cybin-biggest-psychiatric-breakthrough-in-40-years","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Has Cybin hit the biggest breakthrough in 40 years to treat psychiatric disorders? - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","1",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Mental health"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://player.vimeo.com/video/935097473","title":"Collaborating for Improved Mental Health","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/yk-vcGyXaCA","title":"Ted","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/4TgBFsozf2durCCzo2RN8X?si=YpuSBJe8TvOrherlvPF1UA","title":"pod","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"FDA Breakthrough Therapy Designation Granted to Novel Psychedelic Molecule CYB003 for Major Depressive Disorder"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial."}],["$","footer",null,{"children":["$","a",null,{"href":"https://www.pharmacytimes.com/view/fda-breakthrough-therapy-designation-granted-to-novel-psychedelic-molecule-cyb003-for-major-depressive-disorder","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: FDA Breakthrough Therapy Designation Granted to Novel Psychedelic Molecule CYB003 for Major Depressive Disorder - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}],["$","div","2",{"className":"space-y-8","children":[["$","div",null,{"className":"text-center","children":["$","h3",null,{"className":"text-xl font-medium text-white mb-4","children":"Research"}]}],["$","div",null,{"className":"grid gap-6","children":[["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-2 gap-6","children":[[["$","div","0",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/305MUararWg?start=0","title":"change?","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}],["$","div","1",{"className":"aspect-video","children":["$","iframe",null,{"src":"https://www.youtube.com/embed/eIxVfln02Ss?start=0","title":"change","className":"w-full h-full rounded-lg","allowFullScreen":true,"loading":"lazy"}]}]],[["$","div","0",{"className":"aspect-video lg:aspect-auto lg:h-[352px]","children":["$","iframe",null,{"src":"https://open.spotify.com/embed/episode/7KuVqFPQwmP9Aa8GmCkMsp?si=453334c0d99d4759","title":"new","className":"w-full h-full rounded-lg","frameBorder":"0","allow":"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture","loading":"lazy"}]}]]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6","children":[["$","article","0",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200","children":["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h4",null,{"className":"text-lg font-medium text-white mb-2","children":"Cybin: Top Value Psychedelic Stock"}],["$","span",null,{"className":"inline-block px-3 py-1 rounded-full text-xs font-medium bg-green-900/30 text-green-300","children":"Article"}]]}],["$","p",null,{"className":"text-gray-300 text-sm mb-4 line-clamp-3","children":"px-captcha"}],["$","footer",null,{"children":["$","a",null,{"href":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"Read article: Cybin: Top Value Psychedelic Stock - opens in new tab","children":["Read Article",["$","svg",null,{"className":"ml-1 w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"}]}]]}]}]]}]}]]}]]}]]}]]}]]}]}]]}],false,["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative ","children":[["$","div",null,{"id":"team","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Team Members","children":[["$","header",null,{"className":"text-center mb-12","children":[["$","h2",null,{"className":"text-2xl md:text-3xl font-semibold text-white mb-4","children":"Team"}],["$","p",null,{"className":"text-gray-300 max-w-2xl mx-auto","children":"Meet the experienced professionals leading our organization"}]]}],["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-8","children":[["$","article","3648",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233872.jpeg","alt":"Doug Drysdale - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Doug Drysdale"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/dougdrysdale/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Doug Drysdale's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3649",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233903.jpeg","alt":"Aaron Bartlone - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Aaron Bartlone"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/aaronbartlone/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Aaron Bartlone's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3650",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233937.jpeg","alt":"Greg Cavers - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Greg Cavers"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/greg-cavers-1b033b293/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Greg Cavers's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}],["$","article","3651",{"className":"bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden hover:border-[#FFFFFF30] transition-colors duration-200 text-center","children":[["$","div",null,{"className":"relative w-full h-64 bg-gray-800","children":["$","$L18",null,{"src":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233983.jpeg","alt":"Eric So - undefined","fill":true,"className":"object-cover","sizes":"(max-width: 768px) 100vw, (max-width: 1200px) 50vw, 33vw"}]}],["$","div",null,{"className":"p-6","children":[["$","header",null,{"className":"mb-4","children":[["$","h3",null,{"className":"text-xl font-semibold text-white mb-1","children":"Eric So"}],["$","p",null,{"className":"text-blue-400 font-medium","children":"$undefined"}]]}],"$undefined",["$","footer",null,{"children":["$","a",null,{"href":"https://www.linkedin.com/in/eric-so-a5942b3/","target":"_blank","rel":"noopener noreferrer","className":"inline-flex items-center text-blue-400 hover:text-blue-300 text-sm font-medium transition-colors duration-200","aria-label":"View Eric So's LinkedIn profile - opens in new tab","children":[["$","svg",null,{"className":"w-4 h-4 mr-2","fill":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"d":"M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433c-1.144 0-2.063-.926-2.063-2.065 0-1.138.92-2.063 2.063-2.063 1.14 0 2.064.925 2.064 2.063 0 1.139-.925 2.065-2.064 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"}]}],"LinkedIn Profile"]}]}]]}]]}]]}]]}]}]]}],["$","div",null,{"className":"md:gap-8 px-4 sm:px-8 lg:px-16 xl:px-32 w-full relative md:max-w-[800px] mx-auto my-8 md:!px-0","children":[["$","div",null,{"id":"faq","className":"absolute h-20 -top-28 left-0 invisible w-full"}],["$","div",null,{"className":"max-w-[1200px] mx-auto","children":["$","section",null,{"aria-label":"Frequently Asked Questions","children":[["$","header",null,{"className":"flex flex-col w-full items-center mb-4","children":["$","div",null,{"className":"flex flex-col gap-1 md:gap-4","children":[["$","h2",null,{"className":"text-xl md:text-[36px] max-w-[584px] md:w-full md:text-center font-semibold text-white","children":"What the Pro's Are Asking"}],["$","p",null,{"className":"text-dark-text md:text-center text-base max-w-[584px]","children":"Here are the questions that professional investors are asking before making an investment decision."}]]}]}],["$","div",null,{"className":"space-y-4","children":[["$","details","4526",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What is Cybin's strategy to address regulatory hurdles?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin is actively working to navigate regulatory hurdles by focusing on clear, evidence-based trials to demonstrate the safety and efficacy of its therapies. The company is also collaborating with regulatory bodies and experts to ensure compliance with evolving standards. Cybin’s engagement with policymakers and educational efforts around psychedelics should play a key role in expediting the regulatory approval process. The company’s leadership in trial design and patient safety protocols should help it stay ahead of potential roadblocks.

"}}]}]]}],["$","details","4527",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What are Cybin’s plans for post-approval commercialization?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"Cybin navigates the restrictive regulatory environment through a multifaceted strategy. The company actively engages with regulatory bodies like the FDA to ensure its clinical trials meet stringent standards, as evidenced by its FDA clearance for a Phase 2a study of CYB004 for Generalized Anxiety Disorder. Cybin also maintains a strong intellectual property portfolio, with over 70 granted patents and 220 pending applications, which not only secures its competitive position but also bolsters its regulatory efforts by showcasing the novelty of its compounds."}}]}]]}],["$","details","4528",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"How do Cybin's therapies compare to existing treatments in the market?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin plans to commercialize its therapies through a combination of direct sales, partnerships with pharmaceutical companies, and licensing agreements. They intend to leverage strategic collaborations to expand their distribution network globally, targeting both healthcare providers and direct-to-consumer markets. Additionally, Cybin is focusing on educating healthcare professionals and integrating its treatments into existing mental health care systems. Effective marketing strategies and strong relationships with distributors will be key to ensuring successful commercialization.

"}}]}]]}],["$","details","4529",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"How does Cybin plan to manage competition in the psychedelics industry?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

Cybin differentiates itself from competitors through its strong clinical trial progress, proprietary delivery methods, and strategic partnerships. The company is focused on advancing its pipeline, which includes treatments for anxiety, addiction, and depression, offering a diversified approach to mental health. By maintaining a deep commitment to research and keeping up with regulatory changes, Cybin can stay ahead of the curve. Additionally, its emphasis on patient safety and treatment efficacy sets it apart from other players in the field.

"}}]}]]}],["$","details","4530",{"className":"group bg-[#1B1A1F] border border-[#FFFFFF15] rounded-lg overflow-hidden","children":[["$","summary",null,{"className":"flex items-center justify-between p-4 cursor-pointer hover:bg-[#2A2930] transition-colors duration-200","children":[["$","h3",null,{"className":"text-white font-medium pr-4","children":"What is the timeline for CYB003 and other therapies to reach the market?"}],["$","svg",null,{"className":"w-5 h-5 text-gray-400 transform transition-transform duration-200 group-open:rotate-180 flex-shrink-0","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","aria-hidden":"true","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M19 9l-7 7-7-7"}]}]]}],["$","div",null,{"className":"px-4 pb-4","children":["$","div",null,{"className":"text-[#D9D7DB] prose prose-invert max-w-none prose-sm","dangerouslySetInnerHTML":{"__html":"

CYB003’s timeline to market is primarily dependent on the successful completion of Phase 3 trials, with results expected to be pivotal for regulatory approval. The anticipated timeline for market approval for CYB003 is around 2026, depending on the trial outcomes and regulatory review processes. Cybin is also working on expanding its pipeline to include treatments for addiction and anxiety, which could diversify its product offerings. In the medium-to-long term, Cybin expects these therapies to be available in key global markets by 2027.

"}}]}]]}]]}]]}]}]]}]]}],["$","$Lb",null,{"id":"financial-product-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"FinancialProduct\",\"name\":\"Cybin\",\"industry\":\"Healthcare\",\"description\":\"Cybin is paving the way for psychedelic medicine to treat mental health disorders, positioning itself at the forefront of a growing industry that could revolutionize psychiatry.\",\"url\":\"https://app.curationconnect.com/company/Cybin-24509\",\"image\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172970.jpeg\",\"identifier\":\"CYBN\",\"exchange\":\"NYSEAMERICAN\",\"price\":8.05,\"priceCurrency\":\"USD\",\"priceChange\":-3.57,\"marketCap\":193038000,\"peRatio\":0,\"provider\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"url\":\"https://app.curationconnect.com\"}}"}}],["$","$Lb",null,{"id":"hero-video-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"VideoObject\",\"name\":\"Cybin Overview Video\",\"description\":\"Cybin is paving the way for psychedelic medicine to treat mental health disorders, positioning itself at the forefront of a growing industry that could revolutionize psychiatry.\",\"thumbnailUrl\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172970.jpeg\",\"uploadDate\":\"2025-06-16T18:01:04.222Z\",\"embedUrl\":\"https://www.youtube.com/embed/qvC6xyiUbw8\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://app.curationconnect.com/logo.png\"}}}"}}],["$","$Lb",null,{"id":"ceo-interview-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"VideoObject\",\"name\":\"CEO Interview\",\"description\":\"Interview with the CEO of Cybin\",\"thumbnailUrl\":\"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172970.jpeg\",\"uploadDate\":\"2025-06-16T18:01:04.222Z\",\"embedUrl\":\"https://www.youtube.com/embed/qZWGF2M4vwE\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"Curation Connect\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://app.curationconnect.com/logo.png\"}}}"}}],["$","$Lb",null,{"id":"faq-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$19"}}],false,["$","$Lb",null,{"id":"team-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1a"}}],["$","$Lb",null,{"id":"investment-thesis-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1b"}}],["$","$Lb",null,{"id":"experts-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1c"}}],["$","$Lb",null,{"id":"investor-materials-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1d"}}],["$","$Lb",null,{"id":"external-insights-schema","type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$1e"}}],["$","div",null,{"className":"w-full","children":["$","$L1f",null,{"data":{"project_id":null,"showcase_id":1815,"assistant_id":"asst_IRmPeAuVfPFOA7dRgK3bw1Dr","enable_curation_ai":true,"agent_id":null,"intent":null,"title":"Cybin","description":"Cybin is a life sciences biotechnology company developing differentiated, next-generation therapeutics to improve clinical outcomes and address key unmet needs for people with mental health conditions","type":"text","private_showcase":false,"logo":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172970.jpeg","x_link":"https://www.linkedin.com/company/cybin/","showcase_heading":"Psychedelic Potential","executive_summary_title":"Strong Position in the Psychedelics Space","executive_summary":"

","investor_relations_link":"https://ir.cybin.com/overview/default.aspx","investor_relations_label":"Investor Relations","graph_link":"https://jika.io/embed/area-chart?symbol=CYBN&selection=one_year&closeKey=close&boxShadow=true&graphColor=1652f0&textColor=161c2d&backgroundColor=FFFFFF&fontFamily=Nunito","contact_email":"Nirav.Karia@curationcorp.com","slug":"Cybin-24509","status":"live","usp_cta":null,"usp_cta_link":null,"catalyst_cta":null,"catalyst_cta_link":null,"teaser_video":"https://www.youtube.com/watch?v=qvC6xyiUbw8","teaser_video_iframe_url":"https://www.youtube.com/embed/qvC6xyiUbw8","teaser_video_label":"Watch Video","teaser_video_title":null,"teaser_video_caption":null,"x_link_label":"Follow the stock","hero_caption":"Cybin is paving the way for psychedelic medicine to treat mental health disorders, positioning itself at the forefront of a growing industry that could revolutionize psychiatry.","hero_cta_label":"Follow the stock","hero_cta_link":"https://www.linkedin.com/company/cybin/","hubspot_enabled":false,"disclaimer":null,"discovery_cover_image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741172892.jpeg","discovery_caption":"Innovating mental healthcare treatments","updated_at":"2025-05-02 12:33:10","usps":[{"title":"Expanding Market for Psychedelic Medicine","description":"

","video":null,"video_iframe_url":null},{"title":"Advancing Clinical Pipeline","description":"

","video":null,"video_iframe_url":null},{"title":"Strategic Partnerships and Industry Momentum","description":"

","video":null,"video_iframe_url":null}],"company_contents":[{"theme":"Key Investor Materials","contents":[{"title":"R&D briefing November 2023","content":"https://www.youtube.com/watch?v=8mP-z_I6cAk","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/8mP-z_I6cAk","showcase_company_content_theme_id":2597},{"title":"Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results","content":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Initiates-PARADIGM-A-Multinational-Pivotal-Phase-3-Program-Evaluating-CYB003-for-the-Adjunctive-Treatment-of-Major-Depressive-Disorder-and-Reports-Second-Quarter-Financial-Results/default.aspx","type":"article","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2597},{"title":"Corporate Presentation September 2024","content":"https://s28.q4cdn.com/259445127/files/CYBN-Corporate-Deck-September-2024-Website-Final.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2597},{"title":"CYB003 Breakthrough Therapy Designation and Phase 2 Durability Data in MDD","content":"https://s28.q4cdn.com/259445127/files/CYBN-CYB003-Program-Update-March-13-2024-Final.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2597}]},{"theme":"Pipeline","contents":[{"title":"Pipeline","content":"https://www.youtube.com/watch?v=dUn2QI5Mtgs","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/dUn2QI5Mtgs","showcase_company_content_theme_id":2598},{"title":"Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder","content":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Grant-of-Additional-U.S.-Patent-in-Support-of-its-CYB003-Breakthrough-Therapy-Program-for-Major-Depressive-Disorder/default.aspx","type":"article","description":"Leading the Industry in Therapeutic Development & Innovative Drug Delivery. 16 patents cover a range of novel psychedelic compounds.","content_iframe_url":null,"showcase_company_content_theme_id":2598},{"title":"Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder","content":"https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Completion-of-FDA-Type-B-Initial-Breakthrough-Therapy-Meeting-and-Plans-for-CYB003-Phase-3-Program-in-Major-Depressive-Disorder/default.aspx","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2598},{"title":"Development Pipeline","content":"https://cybin.com/development-pipeline/","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2598}]}],"external_insights":[{"theme":"Impact","contents":[{"title":"Ted talk","content":"https://www.youtube.com/watch?v=QCQoBAzMP2E","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/QCQoBAzMP2E?start=0","showcase_external_insight_theme_id":2526},{"title":"Has Cybin hit the biggest breakthrough in 40 years to treat psychiatric disorders?","content":"https://www.outsourcing-pharma.com/Article/2024/05/30/Cybin-biggest-psychiatric-breakthrough-in-40-years","type":"article","description":"In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.","content_iframe_url":null,"showcase_external_insight_theme_id":2526},{"title":"Interview","content":"https://open.spotify.com/embed/episode/0KdG6aIcKNGlK9KdYjmOst?si=83bf93d2a14846fa","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2526},{"title":"How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks","content":"https://www.youtube.com/watch?v=D2wuKe5dAJw","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/D2wuKe5dAJw?start=0","showcase_external_insight_theme_id":2526}]},{"theme":"Mental health","contents":[{"title":"Collaborating for Improved Mental Health","content":"https://vimeo.com/935097473","type":"video","description":"This is "Collaborating for Improved Mental Health" by Milken Institute on Vimeo, the home for high quality videos and the people who love them.","content_iframe_url":"https://player.vimeo.com/video/935097473","showcase_external_insight_theme_id":2527},{"title":"Ted","content":"https://www.youtube.com/watch?v=yk-vcGyXaCA","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/yk-vcGyXaCA","showcase_external_insight_theme_id":2527},{"title":"FDA Breakthrough Therapy Designation Granted to Novel Psychedelic Molecule CYB003 for Major Depressive Disorder","content":"https://www.pharmacytimes.com/view/fda-breakthrough-therapy-designation-granted-to-novel-psychedelic-molecule-cyb003-for-major-depressive-disorder","type":"article","description":"At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.","content_iframe_url":null,"showcase_external_insight_theme_id":2527},{"title":"pod","content":"https://open.spotify.com/embed/episode/4TgBFsozf2durCCzo2RN8X?si=YpuSBJe8TvOrherlvPF1UA","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2527}]},{"theme":"Research","contents":[{"title":"change?","content":"https://www.youtube.com/watch?v=305MUararWg","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/305MUararWg?start=0","showcase_external_insight_theme_id":2528},{"title":"change","content":"https://www.youtube.com/watch?v=eIxVfln02Ss","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/eIxVfln02Ss?start=0","showcase_external_insight_theme_id":2528},{"title":"Cybin: Top Value Psychedelic Stock","content":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock","type":"article","description":"px-captcha","content_iframe_url":null,"showcase_external_insight_theme_id":2528},{"title":"new","content":"https://open.spotify.com/embed/episode/7KuVqFPQwmP9Aa8GmCkMsp?si=453334c0d99d4759","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2528}]}],"experts":[{"id":3741,"name":"Biospace","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162586.jpeg","expertise":"Biopharma Publications","audience":"115k","x_link":"https://x.com/biospace","linkedin":"https://www.linkedin.com/company/biospaceinc/","website":"https://www.biospace.com/","quotes":[{"id":5184,"showcase_expert_id":3741,"platform":"article","type":"text","content":"\"Anxiety disorders affect over 40 million adults in the United States each year. In the U.S., GAD is the most common anxiety disorder seen in primary care, with a 12-month prevalence of 2.9%\"","cta_label":"Read more","cta_link":"https://www.biospace.com/cybin-initiates-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder#:~:text=Anxiety%20disorders%20affect%20over%2040%20million%20adults%20in%20the%20United%20States%20each%20year.3%20In%20the%20U.S.%2C%20GAD%20is%20the%20most%20common%20anxiety%20disorder%20seen%20in%20primary%20care%2C%20with%20a%2012%2Dmonth%20prevalence%20of%202.9%25","title":null},{"id":5185,"showcase_expert_id":3741,"platform":"article","type":"text","content":"\"Despite the use of existing therapies, 50% of patients with GAD do not respond to first line treatment with antidepressants such as SSRIs and SNRIs\"","cta_label":"Read more","cta_link":"https://www.biospace.com/cybin-initiates-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder#:~:text=Despite%20the%20use%20of%20existing%20therapies%2C%2050%25%20of%20patients%20with%20GAD%20do%20not%20respond%20to%20first%20line%20treatment%20with%20antidepressants%20such%20as%20SSRIs%20and%20SNRIs4%2C%20highlighting%20a%20large%20treatment%20gap%20and%20urgent%20need%20for%20improved%20therapeutic%20options","title":null}]},{"id":3742,"name":"Nature Mental Health","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162890.jpeg","expertise":"Health Journal publication","audience":"5k","x_link":"https://x.com/NatMentHealth","linkedin":null,"website":"https://www.nature.com/natmentalhealth/","quotes":[{"id":5186,"showcase_expert_id":3742,"platform":"x","type":"text","content":"\"Psilocybin & escitalopram create different reconfigurations in the global functional hierarchy of brain dynamics in people with major depressive disorder\"","cta_label":"See more","cta_link":"https://x.com/NatMentHealth/status/1820817244055609466","title":null}]},{"id":3743,"name":"Drug Science","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724163076.jpeg","expertise":"Independent Scientific body","audience":"25.2k","x_link":"https://x.com/Drug_Science","linkedin":null,"website":"https://www.drugscience.org.uk/","quotes":[{"id":5187,"showcase_expert_id":3743,"platform":"x","type":"text","content":"\"Mental health treatment has seen little innovation over the past 50 years. Recent research shows psychedelics can be effective for depression and PTSD. There is growing support from professionals and patients\"","cta_label":"See more","cta_link":"https://x.com/Drug_Science/status/1793564380506055063","title":null}]},{"id":3744,"name":"Dr Bart Ellenbroek","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233592.jpeg","expertise":"Professor of Psychology","audience":"1.3k","x_link":null,"linkedin":"https://www.linkedin.com/in/bartellenbroek/","website":"https://people.wgtn.ac.nz/bart.ellenbroek","quotes":[{"id":5188,"showcase_expert_id":3744,"platform":"youtube","type":"text","content":"\"By 2030 mental health associated costs will be 6 trillion dollars. To put that into perspective it is more than the cost for cancer, diabetes and chronic respiratory diseases combined\"","cta_label":"Watch","cta_link":"https://youtu.be/Ij5hjgsFohw?si=1t0A44LRhwPC8c-E","title":null}]},{"id":3745,"name":"Psychedelic Finance","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724162443.jpeg","expertise":"Investment news in Psychedelic industry","audience":"21.9k","x_link":"https://x.com/Psych_Fin","linkedin":"https://www.linkedin.com/company/forbes-magazine/","website":"https://www.forbes.com","quotes":[{"id":5189,"showcase_expert_id":3745,"platform":"x","type":"text","content":"\"Mental healthcare and addiction treatments have not had any meaningful breakthroughs in decades. The psychedelic movement is happening because we urgently need new answers.\"","cta_label":"See more","cta_link":"https://x.com/Psych_Fin/status/1706300982483702143","title":null}]},{"id":3746,"name":"Forbes","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724163576.jpeg","expertise":"Information","audience":"20.1m","x_link":"https://x.com/Forbes","linkedin":"https://www.linkedin.com/company/forbes-magazine/","website":"https://www.forbes.com","quotes":[{"id":5190,"showcase_expert_id":3746,"platform":"article","type":"text","content":"\"The psychedelic drug market is projected to soar to $7.2 billion by 2029, reflecting a 55% compound annual growth rate (CAGR) and further showing its powerful potential in the field of medicine.\"","cta_label":"Read more","cta_link":"https://www.forbes.com/sites/benjaminadams/2023/09/29/these-three-drugs-could-make-up-over-half-of-forecasted-psychedelic-sales-by-2029/","title":null},{"id":5191,"showcase_expert_id":3746,"platform":"article","type":"text","content":"\"By 2029, the top three psychedelic drugs—Atai Life Sciences/Otsuka Pharmaceutical’s PCN-101, Cybin’s CYB-003, and Small Pharma’s SPL-026—are projected to represent 52% of the market’s forecasted sales\"","cta_label":"Read more","cta_link":"https://www.forbes.com/sites/benjaminadams/2023/09/29/these-three-drugs-could-make-up-over-half-of-forecasted-psychedelic-sales-by-2029/","title":null}]},{"id":3747,"name":"Jason Najum","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1729170126.jpeg","expertise":"Analyst","audience":"579","x_link":null,"linkedin":"https://www.linkedin.com/in/jason-najum-36a905169/","website":null,"quotes":[{"id":5192,"showcase_expert_id":3747,"platform":"seeking_alpha","type":"text","content":"\"After only two doses at 16 milligrams, 75% of those patients were responding to treatment and no longer met the criteria for depression — meaning 75% of patients were in remission from depression after just two doses.\"","cta_label":"Read more","cta_link":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=After%20only%20two%20doses%20at%2016%20milligrams%2C%2075%25%20of%20those%20patients%20were%20responding%20to%20treatment%20and%20no%20longer%20met%20the%20criteria%20for%20depression%20%E2%80%94%20meaning%2075%25%20of%20patients%20were%20in%20remission%20from%20depression%20after%20just%20two%20doses.","title":null},{"id":5193,"showcase_expert_id":3747,"platform":"seeking_alpha","type":"text","content":"\"Cybin could be the best value bet among this group of biotech pioneers\"","cta_label":"Read more","cta_link":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=Cybin%20could%20be%20the%20best%20value%20bet%20among%20this%20group%20of%20biotech%20pioneers.","title":null},{"id":5194,"showcase_expert_id":3747,"platform":"seeking_alpha","type":"text","content":"\"Cybin offers a very interesting entry point for investors looking to capitalize on the growth potential of the psychedelic medicine market.\"","cta_label":"Read more","cta_link":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock","title":null},{"id":5195,"showcase_expert_id":3747,"platform":"seeking_alpha","type":"text","content":"\"The data show that Cybin’s CYB003 has scored over 10 times better in depression symptoms vs historic competitors\"","cta_label":"Read more","cta_link":"https://seekingalpha.com/article/4726901-cybin-top-value-psychedelic-stock#:~:text=the%20data%20show%20that%20Cybin%E2%80%99s%20CYB003%20has%20scored%20over%2010%20times%20better%20in%20depression%20symptoms%20vs%20historic%20competitors","title":null}]}],"catalysts":[{"id":3985,"showcase_id":1815,"type":"short","description":"

Ongoing Phase 3 Trial Progress for CYB003
The ongoing Phase 3 trial for CYB003, a psilocybin-based therapy for Major Depressive Disorder, represents a critical short-term catalyst. Positive results could expedite approval and increase investor confidence in Cybin’s clinical pipeline, driving the stock price higher.
Regulatory Updates and Policy Shifts
Changes in legislation and shifting public attitudes toward psychedelic therapies are key short-term catalysts. Regulatory approvals, particularly in North America and Europe, could significantly boost the momentum for Cybin’s treatments, making these updates crucial for short-term growth.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3986,"showcase_id":1815,"type":"medium","description":"

Expansion into New Indications
Cybin is expanding its research beyond depression to include indications like anxiety and addiction. The potential approval and subsequent success in these areas could drive significant revenue growth and diversify the company’s portfolio, acting as a medium-term catalyst.
Strategic Partnerships and Licensing Deals
In the medium term, Cybin’s ability to forge strategic partnerships with pharmaceutical companies or healthcare providers will play a critical role in accelerating product development and commercialization. Licensing deals or collaborations could further strengthen its pipeline and provide additional revenue streams.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3987,"showcase_id":1815,"type":"long","description":"

Market Adoption and Integration of Psychedelic Medicine
Long-term catalysts include the growing acceptance and adoption of psychedelic-assisted treatments for mental health. As the global healthcare system continues to embrace alternative treatments for depression, anxiety, and addiction, Cybin could see widespread integration of its therapies, leading to sustained growth.
Commercialization of CYB003 and Other Therapies
Once regulatory approvals are obtained, Cybin’s therapies, particularly CYB003, could become major revenue drivers. Long-term, Cybin’s ability to successfully commercialize its products across global markets and implement its pricing strategy will determine the company’s position as a market leader in psychedelic medicine.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null}],"ceo_interviews":[{"id":2020,"showcase_id":1815,"title":null,"video":"https://www.youtube.com/watch?v=qZWGF2M4vwE","video_iframe_url":"https://www.youtube.com/embed/qZWGF2M4vwE","cover_image":null}],"faqs":[{"id":4526,"showcase_id":1815,"question":"What is Cybin's strategy to address regulatory hurdles?","answer":"

","video":null,"video_iframe_url":null},{"id":4527,"showcase_id":1815,"question":"What are Cybin’s plans for post-approval commercialization?","answer":"Cybin navigates the restrictive regulatory environment through a multifaceted strategy. The company actively engages with regulatory bodies like the FDA to ensure its clinical trials meet stringent standards, as evidenced by its FDA clearance for a Phase 2a study of CYB004 for Generalized Anxiety Disorder. Cybin also maintains a strong intellectual property portfolio, with over 70 granted patents and 220 pending applications, which not only secures its competitive position but also bolsters its regulatory efforts by showcasing the novelty of its compounds.","video":null,"video_iframe_url":null},{"id":4528,"showcase_id":1815,"question":"How do Cybin's therapies compare to existing treatments in the market?","answer":"

","video":null,"video_iframe_url":null},{"id":4529,"showcase_id":1815,"question":"How does Cybin plan to manage competition in the psychedelics industry?","answer":"

","video":null,"video_iframe_url":null},{"id":4530,"showcase_id":1815,"question":"What is the timeline for CYB003 and other therapies to reach the market?","answer":"

","video":null,"video_iframe_url":null}],"researches":[],"articles":[],"team_members":[{"id":3648,"showcase_id":1815,"name":"Doug Drysdale","role":"Chief Executive Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233872.jpeg","linkedin":"https://www.linkedin.com/in/dougdrysdale/","x_link":"https://x.com/insidepharma","description":"Doug, an experienced CEO and Corporate Director has led multiple pharmaceutical companies for the last 30 years, raised $4 billion, completed 15 acquisitions, and significantly increased revenues and enterprise value. He was recognized as Entrepreneur of the Year in 2012"},{"id":3649,"showcase_id":1815,"name":"Aaron Bartlone","role":"Chief Operating Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233903.jpeg","linkedin":"https://www.linkedin.com/in/aaronbartlone/","x_link":"https://x.com/AaronBartlone","description":"Aaron is the Former Chief Quality, Patient Safety, HSE & Risk Officer and President at UCB, Inc., leading global teams and US operations. Held various director roles at Eli Lilly."},{"id":3650,"showcase_id":1815,"name":"Greg Cavers","role":"Chief Financial Officer","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233937.jpeg","linkedin":"https://www.linkedin.com/in/greg-cavers-1b033b293/","x_link":null,"description":"Greg Cavers, Chief Financial Officer with 15+ years of experience in financial operations, regulatory reporting, and IFRS, has held senior roles at Ontario Securities Commission, Scotiabank, Global Maxfin Investments, and CIBC."},{"id":3651,"showcase_id":1815,"name":"Eric So","role":"Co-founder, Executive Chairman and President","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1724233983.jpeg","linkedin":"https://www.linkedin.com/in/eric-so-a5942b3/","x_link":null,"description":"Co-founder and Managing Director of Trinity Venture Partners Inc., with extensive experience as a founder, investor, and advisor. He began his career in corporate law and has raised hundreds of millions for companies, facilitating exits and liquidity events. He holds a B.Sc. in Anatomy and Cell Biology a Bachelor of Laws"}],"showcase_stocks":{"id":1705,"showcase_id":1815,"exchange":"NYSEAMERICAN","symbol":"CYBN","price":8.05,"change_percent":-3.57,"average_volume":323100,"marketcap":193038000,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null},"stock_symbol":"NYSE:CYBN","exchange":"NYSEAMERICAN","symbol":"CYBN","price":8.05,"change_percent":-3.57,"average_volume":323100,"marketcap":193038000,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null,"target_price_change_percentage":null,"buy":[{"id":2177,"showcase_id":1815,"type":"buy","title":"Expanding Market for Psychedelic Medicine","caption":"The global mental health crisis and the promise of psychedelic medicine for depression, PTSD, and addiction present Cybin with a unique opportunity to lead in a rapidly growing market."},{"id":2178,"showcase_id":1815,"type":"buy","title":"Advancing Clinical Pipeline","caption":"Cybin’s lead candidate, CYB003, is in Phase 3 trials for Major Depressive Disorder, with positive preliminary results. The company is also expanding its pipeline into other mental health conditions like anxiety and addiction."},{"id":2179,"showcase_id":1815,"type":"buy","title":"Strategic Partnerships and Industry Momentum","caption":"Cybin benefits from strong partnerships with academic and industry leaders, positioning it well to leverage growing institutional interest and regulatory support for psychedelic medicine as the industry gains momentum."}],"sell":[{"id":2180,"showcase_id":1815,"type":"sell","title":"Strategic Partnerships and Industry Momentum","caption":"Despite progress, regulatory approval for psychedelics remains uncertain. Unexpected delays or challenges from regulatory bodies could push back timelines, impacting market entry and revenue potential."},{"id":2181,"showcase_id":1815,"type":"sell","title":"Competition in Psychedelic Market","caption":"The psychedelics market is increasingly crowded. Competitors with similar treatment models or more established pipelines could limit Cybin’s market share, putting pressure on pricing and growth."},{"id":2182,"showcase_id":1815,"type":"sell","title":"Execution and Commercialization Risks","caption":"Cybin faces the challenge of executing its post-approval commercialization plan, managing partnerships, and gaining market access. Effective execution will be crucial for achieving long-term growth and maintaining competitive advantages."}],"key_risks":[{"id":924,"showcase_id":1815,"title":"Regulatory Delays and Uncertainty","description":"

","video":"https://google.com","video_iframe_url":null},{"id":925,"showcase_id":1815,"title":"Competitive Landscape","description":"

","video":"https://google.com","video_iframe_url":null},{"id":926,"showcase_id":1815,"title":"Execution Risks and Commercialization Challenges","description":"

","video":"https://google.com","video_iframe_url":null}],"industries":[{"id":81,"industry_id":6,"name":"Healthcare"}],"tag":{"id":78,"showcase_id":1815,"company_size":"micro","region":"canada","type_of_stock":"gowth","revenue_stage":"pre_revenue","mag7":false,"buy_back":false,"income":false,"debt":false,"management_ownership_more_than_5_percent":false},"prompts":[{"id":673,"showcase_id":1815,"sequence":1,"question":"What are the company's revenues?"},{"id":674,"showcase_id":1815,"sequence":2,"question":"Is the company profitable?"},{"id":675,"showcase_id":1815,"sequence":3,"question":"How much cash does it have?"},{"id":676,"showcase_id":1815,"sequence":4,"question":"Who are the top 5 biggest shareholders?"},{"id":677,"showcase_id":1815,"sequence":5,"question":"Tell me about the CEO's background"},{"id":678,"showcase_id":1815,"sequence":6,"question":"Who are the major competitors?"},{"id":679,"showcase_id":1815,"sequence":7,"question":"What is the market opportunity?"}]},"slug":"Cybin-24509"}]}]]}]